1023 related articles for article (PubMed ID: 17989688)
1. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
3. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
4. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
5. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
6. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
7. [Eculizumab in paroxysmal nocturnal hemoglobinuria].
Socié G; Varoqueaux N; Peffault de Latour R
Med Sci (Paris); 2009 Dec; 25(12):1126-9. PubMed ID: 20035691
[TBL] [Abstract][Full Text] [Related]
8. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
9. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
Guasch A
Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
[No Abstract] [Full Text] [Related]
10. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
Richards SJ; Hill A; Hillmen P
Cytometry B Clin Cytom; 2007 Sep; 72(5):291-8. PubMed ID: 17549742
[TBL] [Abstract][Full Text] [Related]
11. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK; Kavanagh D
Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
[TBL] [Abstract][Full Text] [Related]
12. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
Szer J; Hill A; Weitz IC
Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
[TBL] [Abstract][Full Text] [Related]
13. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.
Luzzatto L; Gianfaldoni G
Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130
[TBL] [Abstract][Full Text] [Related]
15. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
Röth A; Dührsen U
Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
17. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
Varela JC; Brodsky RA
Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
[TBL] [Abstract][Full Text] [Related]
18. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Dmytrijuk A; Robie-Suh K; Cohen MH; Rieves D; Weiss K; Pazdur R
Oncologist; 2008 Sep; 13(9):993-1000. PubMed ID: 18784156
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab for paroxysmal nocturnal haemoglobinuria.
Parker C
Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
[TBL] [Abstract][Full Text] [Related]
20. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
